S_ury 1The aims of the trial were to estabish the response rate and determine the toxxity of combination chemotherapy with ifospamide, vincristine and spatin (HOP regimn) in advanced metastatic seminoma and to study the role of post-chemotherapy consdation treatment Patients with bulky metasatic non-sfetoprotein-producing seminos were eligible for this phase II study [serum human chorionic gonadotropin<20OUI1' (<40ng1-')] if they pested with abdomial masses > 10cm or had extra-gonadal seminoma or had relapsed after previous radiotherapy. The HOP regimen consisted of four 3-weekly cycles of the following drug combination ifosphamide (days 1-5, 1 2mg m2 day-'), vincristin (day 1, 2mg) and cisplatin (days 1-5, 20mgm-2 day-'). Residual masses persisting 6 months after chemotherapy could be considered for consolidation surgery or radiotherapy. 
platin (DDP)-based chemotherapy is fiequently used in the more advanced cases (stage>,HC) (Wettlaufer, 1984; Friedman et al., 1985; Pizzocaro et al., 1986; Fossa et al., 1987; Loehrer et al., 1987; Wilkinson et al., 1988; Horwich et al., 1992; Clemm et al., 1989; Schmoll et al., 1993; Mencel et al., 1994) . Up to 1987 most institutions used the same or a similar combination of cytostatics in patients with nonseminoma. During the 1980s oncologists lared to treat patients with non-seminomatous testicular cancer according to prognostic groups, mainly determined by the tumour burden (MRC, 1985; Stoter et al., 1987; Bosl et al., 1988; Einhorn et al., 1989) . For seminoma patients no such prognostic grouping existed in 1987. However, many cliniians considered patients with stage>IEID as a 'high-risk' group (HID = retroperitoneal tumours > 10 cm in diameter). Patients with extragonadal seminoma, who often present with very bulky tumours, may also arbitrarily be categorised as highrisk cases. Patients relapsing after previous radiotherapy or non-cisplatin-containing chemotherapy have also been consided as a 'high-risk' group by several investigators (Fossa et al., 1987; Loehrer et al., 1987) .
Most authors (Wettlaufer, 1984; Friedman et al., 1985; Pizzocaro et al., 1986; FossA et al., 1987; Loehrer et al., 1987; Wilkinson et al., 1988) have used three-or even four-drug combination chemotherapy in patients with metastatic seminoma. Vimblastn, cyclophosphamide, adriamycin, bleomycin and/or vincristine have most often been selected. The combination of cisplatin and etoposide today may be considered to be the standard treatment (Motzer, 1993) . Based on experience from patients with non-seminomatous germ cel cancer, bleomycin has been most often appLied as the drug of choice. However, bleomycin is associated with the risk of hmg compiations in these often elderly patients with an age-related reduction in kidney function. Another active drug in the treatment of testicular cancer is ifosphamide (IFM). As alkylating agents were used with some sucess in the treatment of advanced seminoma before the introduction of cisplatin (MacKenzie, 1966) , [FM may (Wettlaufer, 1984) .
In (Table I ).
Four weeks after the last chemotherapy cycle the patients were restaged by CT and other appropriate methods (for example by bone scan in case of initial skeletal metastases). In the case of complete response (see below) no further treatment was given. In the case of residual tumour masses a fine-needle aspiration biopsy was to be performed dunrng week 13, if possible. If no malignant residual tumour cells were found, the patient was to be observed at 6 week intervals for the first 6 months without any consolidation treatment as long as serial CT scans showed continuous shrinkage of the residual post-chemotherapy masses. If the residual mass stopped shrinking within 6 months of chemotherapy or if there was a remaining mass 6 months after discontinuation of chemotherapy, post-chemotherapy resection of the masses was considered. No further treatment was given to patients without vital malignant tumour cells in the operation specimen, whereas further chemotherapy or radiotherapy (at the clinician's discretion) was to be given to patients in whom the histological sections or fine-needle aspirates revealed residual malignant tumour. If surgery was judged to be impossible in an individual patient (mediastinal mass, poor general condition and/or old age), radiotherapy to the tumour-bearing area was recommended.
Evaluation of response Response evaluation was to be done in all eligible patients regardless of the number of chemotherapy cycles which were given ('intention to treat'). Measurement of the indicator 
Results
From March 1988 to January 1992 13 institutions entered 51 patients with histologically proven seminoma into the study (Table II) . Nine patients were finally deemed to be ineligible.
For one of the 51 patients, no case record forms were received at the data centre after registration. In three patients revision of the pathological sections revealed histology incompatible with seminoma. Two other patients presenting with small multiple lung densities were initially categorised as having stage IV disease. It subsequently became obvious that the pulmonary nodules were sequelae of virus-induced pneu- Residual masses and consolidation treatment Immediately after HOP chemotherapy the retroperitoneal mass had completely disappeared in only 1 of 17 previously non-irradiated patients in whom the initial retroperitoneal lesion was . 100 mm (Figure la and b) . In six patients the residual mass was <30 mm: three of these masses disappeared completely without further treatment during the first year of follow-up. The other three lesions remained unchanged. In ten patients a residual mass of > 30 mm persisted after four HOP cycles. In three of these ten patients the lesion was resected within 6 months after chemotherapy. Shrinkage by >50% of the immediate post-chemotherapy size within the first year after chemotherapy was observed in three of the remaining seven patients, in one of them leading to CR. One of these 3 partially responding lesions was irradiated 11 months after HOP therapy. In the last four patients the retropenrtoneal mass persisted virtually Thomas, 1991) have shown that patients who have a small-volume mediastinal or supraclavicular relapse after radiotherapy for stage I seminoma can be cured by further radiotherapy alone. Retrospectively one has to admit that not all of our patients relapsing after radiotherapy represented 'high-risk' cases. The HOP regimen was probably overtreatment in some of the previously irradiated patients with limited supradiaphragmatic lymph node relapse. However, bNA, not available. when the present phase II study was initiated, no generally accepted high-risk criteria for seminoma existed and the eligibility criteria had to be arbitrarily defined with some support from the literature (Fossa et al., 1987; Loehrer et al., 1987) . However, early reports on recurrent seminoma patients probably inchlde previously irradiated patients with more advanced relapses and thus a high risk of failure of salvage treatment compared with those entered in the present trial.
The optimal combination chemotherapy in high-risk seminoma patients remains a matter of debate. Clinical experience with bleomycin in elderly patients has taught that this drug may be associated with a high-risk of pulmonary complications, in particular if prior mediastinal irradiation has been applied (Lehne and Lote, 1984) . Wettlaufer (1984) has designed a combination drug schedule in which bleomycin is replaced by vincristine, a drug with minimal bone marrow toxicity. The present HOP regimen represets a modification of the Wettlaufer regimen, in which cyclophosphamide is replaced by ifosphamide, and which has shown high activity in germ cell cancer. Compared with the relapse and survival rates from Table IV Several authors have expressed concern about chemotherapy tolerability after previous radiotherapy for seminoma (Pizzocaro et al., 1986; Motzer et al., 1988) . However, according to Pizzocaro et al. (1986) and Fossa and Aamdal (1992) , patients who have received infradiaphragmatic radiotherapy alone tolerate cisplatin-based chemotherapy as well as previously untreated patients. This is also our experience with the HOP chemotherapy. This observation is important as it does not contradict the present recommendation of infradiaphragnatic radiotherapy as standard treatment for seminoma stage I. Whether the combination of moderate-dose infradiaphragmatic radiotherapy and subsequent salvage chemotherapy in relapsing patients leads to an increased risk of long-term toxcity renains to be shown in future studies.
The role of routine consolidation treatment after chemotherapy for advanced seminoma has been intensively discussed (Friedman et al., 1985; Fossa et al., 1987; Motzer et al., 1987; Ellison et al., 1988; Wilkinson et al., 1988; Horwich et al., 1992) . Some authors have recommended the routine removal of residual masses a few months after chemotherapy (Motzert al., 1987) . Others (Schultz et al., 1989; Horwich et al., 1992) have advised observation or radiotherapy to increase the chance of local control. In series which consider post-chemotherapy surgery, 85-90% of the residual masses contain fibrosis and necrosis. As post-chemotherapy surgery in patients with advanced seminoma represents a surgical procedure with a relatively high risk of per-and postoperative complications, it does not seem justified to operate immediately in all patients in whom masses persist after chemotherapy. The present seres supports this recommendation. Patients with lesions persisting after chemotherapy can as a rule be safely observed for up to 1 year, allowing fiuther shrinkage of the mass. Though the present series comprises only ten evaluable patients, this recommendation also refers to residual tumours with a diameter .30 mm after HOP chemotherapy. Lesions of this size have, in some authors' experience, been proven particularly often to contain residual malignancy (Motzer et al., 1987) . In our experience three of three resected residual retroperitoneal masses of that size and one mediastinal esion contained complete necrosis. None of the six patients with long-term prsisting retroperitoneal or mediastinal tumours without consolidation treatment have relapsed after a median observation time of 2.5 years.
Our results underline the difficulies in defining clinical criteria of response to chemotherapy in patients with advanced seminoma. Residual masses persist frequently and are often unsuitable for surgery. Furthermore, a clinical PR often represents a pathological CR. Our experience also indicates that clinicians do not believe in the significnce of fine-needle biopsies, which may miss tiny tumour foci in a large fibrotic mass. If possible, a bidimensionally measurable response should not be assessed before 6 months has elapsed, allowing long-term post-chemotherapy shrinka. The efficacy of chemotherapy in advanced seminoma should, however, preferably be evaluated by more meaningful biological parameters: time to progression and cancer-related survival.
In conclusion, the HOP chemotherapy rgmen is highly effective in patients with bulky metastabtc seminoma (stage > IID, patients relapsing after radiotherapy, extragonadal presentation), but represents a relatively toxic treatment. Less toxic regimens are probably to be preferred in patients with low-volume disease. Previous infradiaphragmatic moderatedose radiotherapy for seminoma does not imply a particularly high nsk of complications. After HOP chemotherapy routine post-chemotherapy consolidation treatment (surgery, radiotherapy) seems unnecessary in the overwhelming majority of the patients. According to our ongoing observations nkage of residual masses can be expected for at least 1 year following chemotherapy.
